 Aprea Therapeutics Inc., APRE, a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointments of Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to its Board of Directors. In addition, Guido Magni, M.D., Ph.D. will step down from the Companys Board of Directors, effective June 30, 2020. Fouad Namouni, M.D., brings more than 20 years of oncology and immuno-oncology drug development expertise, most recently serving as Senior Vice President Head of Oncology Development at Bristol-Myers Squibb BMS, with responsibility for driving product development plans from early-stage clinical development through commercialization. 